OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Queen 1

Are you trying to tell me my assumptions are wrong?
Surely not. Your in love with me just admit it and
try to move on.

All the best my Queen xxxxxxxxxx

I have taken a look at the YOO thread and only hope that this one does not go the same way. Please can we just share info about OXB on this thread as I am really not interested in juvenile chatroom posts, can you two just call it a day there - the next one to make a comment if it's not about OXB loses ok. Thank you.

Robstuff- Ok point taken. Keep your hair on.

Too late, I'm bald :)

Whoops, I lost! A Momentary lapse of concentration. Anyone know when the BIO Convention is? Their lentivector technology i think has excellent licencing potential, a good presentation could lead to some more deals. The bid rumours seem to hve faded which is good news and should mean the sp holding at these levels before the next positive news pushes them above 40p. I still believ 50p by the yr end is easily achievable.

About to announce something big I shouldn't wonder.

Well it's good to see momentum restored as they had been very slowly drifting south again.

MMs know an announcement is imminent, something's been leaked, expect news tomorrow and a big mark up.

May see 40p breached tomorrow

definitely something going on, sp staying up with recent loads of sells - mms accumulating.

Oxford Biomedica PLC
30 June 2005


Oxford BioMedica plc (the 'Company')

Notification of Major Interests in Shares

The Company has received notification from Calyon Corporate and Investment Bank
that on 29 June 2005 Credit Agricole Cheuvreux International Ltd had an interest
in 36,917,000 Oxford BioMedica plc 1p ordinary shares. This represents 9.82% of
the presently issued share capital of the Company, which stands at 375,841,175
shares.

good start for the week

This will be the reason why:

Oxford Biomedica gets 2 new lentivirus patents in China
AFX


LONDON (AFX) - Gene therapy group Oxford Biomedica PLC said it was granted two patents by the Patent Office of the Peoples' Republic of China that have broad claims covering vectors derived from lentiviruses.

These are the first patents covering the commercial use of the company's LentiVector technology in China, it said, adding that China is the only

country in the world with an approved gene therapy product.

The LentiVector technology forms the delivery system for the Oxford Biomedica's neurotherapy pipeline, including products for Parkinson's disease, age-related macular degeneration, motor neuron disease, spinal muscular atrophy and nerve repair.

Patents in China might be more valuable then elswhere with the large growth rate in China.

It will be interesting to see what plans OXB has for deals in China.

The upward trend to 40+ will continue now, large investors (well all shareholders really) will be waiting for that ever more critical update on Trovax and any further partnerships or deals for Lentivector technology will help momentum, this share could quite easily be 1 by the end of yr, the immediate downside is limited as many large institutions now have it on their radars.

There's an interesting new thread called BIOS which includes progress of OXB. There's more and more serious interest in this stock as all their milestones are reached and the race shortens for that cancer cure blockbuster. Expect a much Higher profile for this Company over the coming months which will propell the sp upwards. Once the 40p level has been breached twice, 50p is attainable shortly afterwards and Newsflow will keep the sp up.

1 million share Purchase this morning, encouraging!!

Feel more confident to hold onto my shares seeing that 1m purchase. Hard to buy in on the dips. Seems each high becomes the next low sustained level. IMO

Sorry doubled post

Oxford Biomedica PLC
25 July 2005


FOR IMMEDIATE RELEASE 25 JULY 2005

OXFORD BIOMEDICA IS AWARDED GRANT FOR MONUDIN(R) FROM THE MOTOR NEURONE DISEASE
ASSOCIATION

Oxford, UK: 25 July 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, announced today that the UK Motor Neurone Disease (MND) Association has
awarded a research grant to support preclinical evaluation of MoNuDin for the
treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of motor
neurone disease. The grant is initially for 350,000, which will fund a key
preclinical efficacy study and support preparations for clinical trials. The
Company is targeting the start of clinical development in 2006-07.

MoNuDin is a novel gene therapy product, which delivers a vascular endothelial
growth factor (VEGF) gene, a neuroprotective factor, using the Company's
proprietary LentiVector system. A previous preclinical study of MoNuDin showed
that both onset and progression of disease was slowed and that life expectancy
was extended by 30%, representing one of the most effective therapies reported
in the field to date. These results were published in May 2004 in Nature
magazine (Volume: 429, Issue: 6990 pp: 413-417).

Oxford BioMedica has previously secured financial support for MoNuDin from the
US ALS Association. The MND Association and other US and UK charitable
organisations are considering further sponsorship that could fund initial
clinical trials of MoNuDin in ALS patients. ALS causes adult-onset, progressive
motor neuron degeneration in the brain and spinal cord, resulting in paralysis
and death three to five years after onset in most patients. There is currently
no known cure for motor neurone disease, a condition that affects approximately
100,000 people in Europe and the USA.

Commenting on the grant from the MND Association, Oxford BioMedica's Chief
Executive, Professor Alan Kingsman said: 'We are very pleased to have received
sponsorship from another leading charity. This grant from the MND Association
provides further endorsement of MoNuDin's potential as a treatment of ALS, for
which there is currently no effective therapy. There is considerable interest in
this programme from charities and other organisations, which could lead to
additional financial support'.

-Ends-